MétaCan
Menu
← Back to cohort
Record W4403831485 · doi:10.1681/asn.2024xk3ssn5d

Rilparencel Autologous Cell Therapy in Patients with Diabetes and Advanced CKD: Phase 2 Interim Results

2024· article· en· W4403831485 on OpenAlexaff
Joseph Stavas, Arnold L. Silva, Theodore F. Saad, Emily L. Butler, Navdeep Tangri, Bruce F. Culleton

Bibliographic record

VenueJournal of the American Society of Nephrology · 2024
Typearticle
Languageen
FieldMedicine
TopicPancreatic function and diabetes
Canadian institutionsUniversity of Manitoba
Fundersnot available
KeywordsInterimMedicineDiabetes mellitusInterim analysisInternal medicineIntensive care medicineClinical trialEndocrinologyPolitical science

Abstract

fetched live from OpenAlex

Background: Cell-based therapies in patients with chronic kidney disease (CKD) may repair diseased nephrons and stabilize kidney function. We describe an interim analysis of an open label phase 2 trial (NCT05018416) with rilparencel, an autologous cell product made from kidney biopsy tissue. Methods: The study objectives are to evaluate efficacy and safety measured by change in eGFR slope from baseline to after last injection and procedure- and product-related serious adverse events. Patients with type 1 or 2 diabetes, eGFR 20-50 ml/min/1.73/m2 and UACR 30-5000 mg/g are randomized into one of two cohorts. Cohort 1 subjects receive two percutaneous rilparencel injections: one into the cortex of each kidney 3 to 5 months apart; Cohort 2 subjects receive at least one injection, and a 2nd injection only after a pre-defined biochemical trigger. eGFR slope is presented for only Cohort 1 given its alignment with an ongoing phase 3 trial. Safety data is aggregated across both cohorts. A post-hoc analysis compares eGFR slope in Cohort 1 with a 10:1 matched synthetic control group. The control group was identified from a subject-level clinical trial database and matched with Cohort 1 based on risk of kidney failure (Klinrisk model). Results: 49 subjects received the 1st injection (n=24 Cohort 1; n=25 Cohort 2) and 34 subjects received a 2nd injection (n=22 Cohort 1; n=12 Cohort 2); 28 subjects have not completed the study and remain in follow up (n=11 Cohort 1; n=17 Cohort 2). 13 Cohort 1 subjects have greater than 12 months follow up post 2nd injection. Mean age is 63 yrs; 54% are female. At baseline, mean (SD) eGFR is 27.9 (9.5) ml/min/1.73/m2; median [IQR] UACR is 239 [4, 2392] mg/g. Annualized eGFR slope in Cohort 1 is -1.1 ml/min/1.73/m2/year (95% CI -3.5, 1.3). Average change in eGFR in the matched control group is -4.0 ml/min/1.73/m2 over 12-months. Two hematomas and 2 episodes of acute kidney injury occurred after kidney biopsy; 1 hematoma occurred after 83 injections. There were no product-related SAEs. Conclusion: Interim findings suggest rilparencel can stabilize kidney function in patients with diabetes and advanced CKD. Procedure-related AEs are infrequent and typical given the interventions. A global phase 3 study is ongoing to determine efficacy and safety of rilparencel. Funding: Commercial Support - ProKidney

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.277
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicPancreatic function and diabetes→French-language works237,207→